CD34 and acute myeloid leukemia: Moreover, since murine hematopoiesis was not affected by PIP/56-1 treatment in mice, and colony-forming ability of human CD34+ progenitor cells was not inhibited by PIP/56-1 treatment, PIP/56-1 may be effective for the treatment of EVI1high AML without adverse side effects on hematopoietic stem cells.